Biofrontera Inc (BFRI) - Total Liabilities
Based on the latest financial reports, Biofrontera Inc (BFRI) has total liabilities worth $18.72 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore BFRI net asset momentum to track the company's year-over-year net asset growth rate.
Biofrontera Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how Biofrontera Inc's total liabilities have evolved over time, based on quarterly financial data. See Biofrontera Inc (BFRI) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Biofrontera Inc Competitors by Total Liabilities
The table below lists competitors of Biofrontera Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Klassik Radio AG
XETRA:KA8
|
Germany | €3.80 Million |
|
Grupo Televisa SAB DRC
BA:TV
|
Argentina | AR$122.08 Billion |
|
Soder Sportfiske AB
ST:SODER
|
Sweden | Skr53.00 Million |
|
MOGU Inc
NYSE:MOGU
|
USA | $311.99 Million |
|
Vertice Bhd
KLSE:7240
|
Malaysia | RM25.12 Million |
|
SciDev Limited
F:INFA
|
Germany | €25.18 Million |
|
Mixed Martial Arts Group Limited
NYSE MKT:MMA
|
USA | $5.35 Million |
|
Rougier S.A.
PA:ALRGR
|
France | €57.41 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Biofrontera Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BFRI market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.20 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.76 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biofrontera Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biofrontera Inc (2019–2025)
The table below shows the annual total liabilities of Biofrontera Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $18.08 Million | +2.35% |
| 2024-12-31 | $17.67 Million | -23.64% |
| 2023-12-31 | $23.14 Million | -14.32% |
| 2022-12-31 | $27.01 Million | -35.52% |
| 2021-12-31 | $41.88 Million | +128.73% |
| 2020-12-31 | $18.31 Million | -68.93% |
| 2019-12-31 | $58.93 Million | -- |
About Biofrontera Inc
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquarte… Read more